Dasgupta , A. and Sawant, M.A. and Kavishwar, G. and Lavhale, M. and Sitasawad, S. (2016) AECHL-1 targets breast cancer progression via inhibition of metastasis, prevention of EMT andsuppression of Cancer Stem Cell characteristics. Scientific Report, 6. 38045 .

Preview

Text 22.Dr. Sitasawad S. (Sci. Repot) open access.pdf Download (735Kb) | Preview

Abstract

Triple negative breast cancer (TNBC) features among the most aggressive manifestations of cancer due to its enhanced metastatic potential and immunity to therapeutics which target hormone receptors. Under such scenarios, anti-cancer compounds with an ability to influence multiple targets, or an entire process, will have an advantage over specific signal transduction inhibitors. To counter the metastatic threat it is essential to target cellular components central to the processes of cancer cell migration and adaptation. Our previous work on a novel triterpenoid, AECHL-1, explored its anti-cancer potential, and linked it to elevated ER stress in cancer cells, while its anti-angiogenic potential was credited for its ability to manipulate the cytoskeleton. Here, we broaden its range of action by showing that it curbs the metastatic ability of TNBC cells, both in vitro in MDA-MB-231 cell line and in vivo, in mouse models of metastasis. AECHL-1 does so by disrupting the cytoskeletal network, and also suppressing NF-κB and β-Catenin mediated key molecular pathways. These activities also contributed to AECHL-1 mediated suppression of TGF-β/TNF-α induced Epithelial to Mesenchymal Transition (EMT) and cancer stem cell characteristic. Thus, we present AECHL-1 as a promising therapeutic inhibitor of metastatic disease.

Item Type:	Article
Additional Information:	This is Open Access Article
Subjects:	Cancer Biology
Depositing User:	Mr. Rameshwar Nema
Date Deposited:	28 Dec 2016 09:22
Last Modified:	02 Mar 2021 11:32
URI:	http://nccs.sciencecentral.in/id/eprint/401

Actions (login required)

View Item